JP2000502700A - セフディニルの製造方法 - Google Patents
セフディニルの製造方法Info
- Publication number
- JP2000502700A JP2000502700A JP9524230A JP52423097A JP2000502700A JP 2000502700 A JP2000502700 A JP 2000502700A JP 9524230 A JP9524230 A JP 9524230A JP 52423097 A JP52423097 A JP 52423097A JP 2000502700 A JP2000502700 A JP 2000502700A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- formula
- dimethylacetamide
- reaction
- cefdinir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 title claims abstract description 29
- 229960003719 cefdinir Drugs 0.000 title claims abstract description 29
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 16
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims abstract description 39
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims abstract description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 7
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 claims abstract description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 56
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 33
- 238000006243 chemical reaction Methods 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 12
- FZEVMBJWXHDLDB-ZCFIWIBFSA-N (6r)-5-thia-1-azabicyclo[4.2.0]oct-2-en-8-one Chemical class S1CC=CN2C(=O)C[C@H]21 FZEVMBJWXHDLDB-ZCFIWIBFSA-N 0.000 claims description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 239000002585 base Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- RTXOFQZKPXMALH-PRHODGIISA-N Cefzon Chemical group S1C(N)=NC(C(=NO)C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-PRHODGIISA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 239000002841 Lewis acid Substances 0.000 claims description 6
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical group COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 6
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 claims description 6
- 150000007517 lewis acids Chemical class 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 6
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 4
- 229910015900 BF3 Inorganic materials 0.000 claims description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 4
- 239000007810 chemical reaction solvent Substances 0.000 claims description 4
- 235000019253 formic acid Nutrition 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- 150000001768 cations Chemical class 0.000 claims description 3
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 3
- LULXBAGMGMJJRW-UHFFFAOYSA-N n,2-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)CC(=O)N[Si](C)(C)C LULXBAGMGMJJRW-UHFFFAOYSA-N 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 239000002516 radical scavenger Substances 0.000 claims description 3
- 150000003512 tertiary amines Chemical class 0.000 claims description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- VMPVEPPRYRXYNP-UHFFFAOYSA-I antimony(5+);pentachloride Chemical compound Cl[Sb](Cl)(Cl)(Cl)Cl VMPVEPPRYRXYNP-UHFFFAOYSA-I 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229960002089 ferrous chloride Drugs 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
- 229940071870 hydroiodic acid Drugs 0.000 claims description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical group [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 claims description 2
- 239000003456 ion exchange resin Substances 0.000 claims description 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 2
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 claims description 2
- LWFWUJCJKPUZLV-UHFFFAOYSA-N n-trimethylsilylacetamide Chemical compound CC(=O)N[Si](C)(C)C LWFWUJCJKPUZLV-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000004437 phosphorous atom Chemical group 0.000 claims description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 claims description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 claims 1
- 229930186147 Cephalosporin Natural products 0.000 abstract description 3
- 230000003115 biocidal effect Effects 0.000 abstract description 3
- 229940124587 cephalosporin Drugs 0.000 abstract description 3
- 150000001780 cephalosporins Chemical class 0.000 abstract description 2
- 239000000543 intermediate Substances 0.000 description 33
- -1 aminothiazole compound Chemical class 0.000 description 17
- 239000013078 crystal Substances 0.000 description 12
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 6
- GQLGFBRMCCVQLU-XCGJVMPOSA-N (6r)-7-amino-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1CC(C=C)=C(C(O)=O)N2C(=O)C(N)[C@H]21 GQLGFBRMCCVQLU-XCGJVMPOSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 208000035484 Cellulite Diseases 0.000 description 4
- 206010049752 Peau d'orange Diseases 0.000 description 4
- 230000036232 cellulite Effects 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- YXIWHUQXZSMYRE-UHFFFAOYSA-N 1,3-benzothiazole-2-thiol Chemical compound C1=CC=C2SC(S)=NC2=C1 YXIWHUQXZSMYRE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 238000005169 Debye-Scherrer Methods 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 229950003476 aminothiazole Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000003541 multi-stage reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- SROQACYXAZKMHW-XPJFZRNWSA-N (6R)-4-amino-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound NC1S[C@H]2N(C(=C1C=C)C(=O)O)C(C2)=O SROQACYXAZKMHW-XPJFZRNWSA-N 0.000 description 1
- PQJGENUUFAPGNV-LSWMGQQCSA-N 1,3-benzothiazol-2-ylsulfanyl (2z)-2-(2-amino-1,3-thiazol-4-yl)-2-trityloxyiminoacetate Chemical compound S1C(N)=NC(C(=N\OC(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)\C(=O)OSC=2SC3=CC=CC=C3N=2)=C1 PQJGENUUFAPGNV-LSWMGQQCSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- GJCUBKXYDDLYJA-UHFFFAOYSA-N C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)ON=CC(=O)OSC4=NC5=CC=CC=C5S4 Chemical compound C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3)ON=CC(=O)OSC4=NC5=CC=CC=C5S4 GJCUBKXYDDLYJA-UHFFFAOYSA-N 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- YKOMVDANUPRZMA-GDWJVWIDSA-N diethylphosphinothioyl (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-trityloxyiminoacetate Chemical compound C=1SC(N)=NC=1/C(C(=O)OP(=S)(CC)CC)=N/OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 YKOMVDANUPRZMA-GDWJVWIDSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229940127249 oral antibiotic Drugs 0.000 description 1
- 229940124588 oral cephalosporin Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.下記の式(II) (式中、Phはフェニルを、p−TsOHはp−トルエンスルホン酸を、またD MACはN,N−ジメチルアセトアミドを表す。) のセフディニル中間体のトリチル保護基を酸の存在下で除去することを特徴とす る、下記の式(I) のセフディニルの製造方法。 2.酸が無機酸、有機酸、または酸性水素イオン交換樹脂である請求項1記載の 製造方法。 3.無機酸が塩酸、臭化水素酸、ヨウ化水素酸、硫酸及びルイス酸よりなる群か ら選ばれる請求項2記載の製造方法。 4.ルイス酸が三フッ化ホウ素、三フッ化ホウ素エチルエテレート、塩化アルミ ニウム、五塩化アンチモン、塩化第一鉄、塩化スズ、四塩化チタン及び塩化亜鉛 よりなる群から選ばれる請求項3記載の製造方法。 5.有機酸が酢酸、ギ酸、トリフルオロ酢酸、メタンスルホン酸、ベンゼンスル ホン酸及びp−トルエンスルホン酸よりなる群から選ばれる請求項2記載の製造 方法。 6.ルイス酸または有機酸を用いる場合において、陽イオン捕捉剤の存在下で反 応を行う請求項2記載の製造方法。 7.陽イオン捕捉剤がアニソールである請求項6記載の製造方法。 8.酸を式(II)の化合物に対して1〜20当量の量で用いる請求項1記載の製 造方法。 9.下記の式(II)を有する結晶性セフディニル中間体。 式中、 Phはフェニルを、 p−TsOHはp−トルエンスルホン酸を、 DMACはN,N−ジメチルアセトアミドを表す。 10.下記の表1のX線粉末回折パターンを示す請求項9記載の式(II)の中間体 。 表1.上記の表1で“θ”は回折角を、“d”は格子面間の距離を表し、 “I/Io”は相対強度を表す。 11.下記の式(III)(式中、Zは、 を表し、ここでR′はC1〜C4アルキルまたはフェニルを表し,又は、それらに 付着している酸素及び燐の原子とともに5〜6員複素環を形成することができる 。) の反応性エステルを、溶媒中で塩基の存在下または不存在下で下記の式(IV) の3−セフェム誘導体と反応させた後、p−トルエンスルホン酸を添加すること を特徴とする、下記の式(II) (式中、Phはフェニルを、p−TsOHはp−トルエンスルホン酸を、DMA CはN,N−ジメチルアセトアミドを表す。) の化合物の製造方法。 12.式(IV)の3−セフェム誘導体に対して式(III)の反応性エステルを0. 8〜2.0当量の量で用いる請求項11記載の製造方法。 13.溶媒がN,N−ジメチルアセトアミド単独であり、又は、エタノール、メタ ノール、イソプロパノール、ジエチルエーテル、テトラヒドロフラン、ジオキサ ン、塩化メチレン、クロロホルム、アセトニトリル、エチルアセテート及びアセ トンよりなる群から選ばれた1種以上の化合物とN、N−ジメチルアセトアミド の混合物である請求項11記載の製造方法。 14.反応が−15〜40℃の温度範囲で行われる請求項11記載の製造方法。 15.第3級アミンを塩基として用いる請求項11記載の製造方法。 16.第3級アミンがトリエチルアミンまたはトリ−n−ブチルアミンである請求 項15記載の製造方法。 17.N−トリメチルシリルアセトアミドまたはN,O−ビストリメチルシリルア セトアミドを塩基の不存在下で用いる請求項11記載の製造方法。 18.p−トルエンスルホン酸を式(IV)の3−セフェム誘導体に対して1〜3当 量の量で用いる請求項11記載の製造方法。 19.反応後、後処理過程でジエチルエーテル、ジイソプロピルエーテル及びエチ ルアセテートよりなる群から選ばれる1の化合物を反応溶媒に対して2〜6容積 倍用いる請求項11記載の製造方法。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1995/58694 | 1995-12-27 | ||
| KR1019950058694A KR0174432B1 (ko) | 1995-12-27 | 1995-12-27 | 신규한 결정성 세프디니르 중간체 및 그의 제조방법 |
| KR1019950058695A KR0174431B1 (ko) | 1995-12-27 | 1995-12-27 | 세프디니르의 제조방법 |
| KR1995/58695 | 1995-12-27 | ||
| PCT/KR1996/000250 WO1997024358A1 (en) | 1995-12-27 | 1996-12-26 | Process for preparation of cefdinir |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000502700A true JP2000502700A (ja) | 2000-03-07 |
| JP3948628B2 JP3948628B2 (ja) | 2007-07-25 |
Family
ID=26631527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52423097A Expired - Lifetime JP3948628B2 (ja) | 1995-12-27 | 1996-12-26 | セフディニルの製造方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6093814A (ja) |
| EP (1) | EP0874853B1 (ja) |
| JP (1) | JP3948628B2 (ja) |
| AT (1) | ATE218572T1 (ja) |
| DE (1) | DE69621649T2 (ja) |
| DK (1) | DK0874853T3 (ja) |
| ES (1) | ES2175167T3 (ja) |
| PT (1) | PT874853E (ja) |
| WO (1) | WO1997024358A1 (ja) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001294590A (ja) * | 2000-04-13 | 2001-10-23 | Otsuka Chem Co Ltd | 3−ビニル−セフェム化合物の製造方法 |
| JP2006500356A (ja) * | 2002-08-13 | 2006-01-05 | サンド・アクチエンゲゼルシヤフト | セフジニル中間体 |
| JP2006501305A (ja) * | 2002-10-01 | 2006-01-12 | アンティビオーティコス エッセ.ピ.ア. | セフジニル中間体塩 |
| JPWO2004085443A1 (ja) * | 2003-03-24 | 2006-06-29 | ア・チ・エツセ・ドブフアル・エツセ・ピー・アー | 7−[2−(2−アミノチアゾール−4−イル)−2−ヒドロキシイミノアセトアミド−3−ビニル−3−セフェム−4−カルボン酸(シン異性体)の新規結晶およびその製造方法 |
| JP2008189688A (ja) * | 2001-06-05 | 2008-08-21 | Hanmi Pharm Co Ltd | 結晶性セフジニル酸付加塩及びこれを用いたセフジニルの製造方法 |
| JP2009249380A (ja) * | 2008-04-04 | 2009-10-29 | Daewoong Pharmaceutical Co Ltd | セフジニルの合成に有用な中間体及びこれを用いるセフジニルの製造方法 |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5883247A (en) * | 1996-06-10 | 1999-03-16 | Hoffmann-La Roche Inc. | Preparation of cephem and isooxacephem derivatives |
| AT405283B (de) * | 1997-04-04 | 1999-06-25 | Biochemie Gmbh | Neues kristallines 7-(z)-(2-(2-aminothiazol-4-yl) -2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4- carbonsäure dicyclohexylammoniumsalz und verfahren zu dessen herstellung |
| US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
| ITMI20012364A1 (it) * | 2001-11-09 | 2003-05-09 | Antibioticos Spa | Processo di sintesi della cefixima via alchil-o arilsolfonati |
| EP1458728A1 (en) * | 2001-12-13 | 2004-09-22 | Ranbaxy Laboratories Limited | Crystalline cefdinir potassium dihydrate |
| CN1628118A (zh) * | 2002-04-26 | 2005-06-15 | 兰贝克赛实验室有限公司 | 制备头孢地尼的方法 |
| ITMI20020913A0 (it) * | 2002-04-29 | 2002-04-29 | Acs Dobfar Spa | Nuova forma cristallina del cefdinir |
| WO2004104010A1 (en) * | 2003-05-20 | 2004-12-02 | Ranbaxy Laboratories Limited | Crystalline form of cefdinir |
| US20050137182A1 (en) * | 2003-06-02 | 2005-06-23 | Ramesh Dandala | Novel crystalline form of cefdinir |
| US20040242556A1 (en) * | 2003-06-02 | 2004-12-02 | Ramesh Dandala | Novel crystalline form of cefdinir |
| US20050113355A1 (en) * | 2003-09-12 | 2005-05-26 | Duerst Richard W. | Cefdinir pyridine salt |
| US20050059818A1 (en) * | 2003-09-12 | 2005-03-17 | Duerst Richard W. | Polymorph of a pharmaceutical |
| US20050059819A1 (en) * | 2003-09-12 | 2005-03-17 | Duerst Richard W. | Cefdinir pyridine salt |
| US20060211676A1 (en) * | 2004-03-16 | 2006-09-21 | Devalina Law | Crystalline anhydrous cefdinir and crystalline cefdinir hydrates |
| US20060142261A1 (en) * | 2004-03-16 | 2006-06-29 | Devalina Law | Crystalline anhydrous cefdinir and crystalline cefdinir hydrates |
| US20060142563A1 (en) * | 2004-03-16 | 2006-06-29 | Devalina Law | Crystalline anhydrous cefdinir and crystalline cefdinir hydrates |
| US20050209211A1 (en) * | 2004-03-16 | 2005-09-22 | Devalina Law | Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir |
| US20060069079A1 (en) * | 2004-09-27 | 2006-03-30 | Sever Nancy E | Stable amorphous cefdinir |
| US20050245738A1 (en) * | 2004-05-03 | 2005-11-03 | Lupin Ltd | Stable bioavailable crystalline form or cefdinir and a process for the preparation thereof |
| WO2006010978A1 (en) * | 2004-06-30 | 2006-02-02 | Wockhardt Limited | Cefdinir polymorphic forms, and imidazole salt |
| WO2006018807A1 (en) * | 2004-08-16 | 2006-02-23 | Ranbaxy Laboratories Limited | Crystalline forms of cefdinir |
| MX2007006018A (es) * | 2004-11-30 | 2007-06-07 | Astellas Pharma Inc | Suspension farmaceutica oral novedosa de cristal de cefdinir. |
| EP1848724A2 (en) * | 2005-10-31 | 2007-10-31 | Teva Pharmaceutical Industries Ltd | Process for the preparation of cefdinir |
| US20070128268A1 (en) * | 2005-12-07 | 2007-06-07 | Herwig Jennewein | Pharmaceutical compositions comprising an antibiotic |
| US8466096B2 (en) * | 2007-04-26 | 2013-06-18 | Afton Chemical Corporation | 1,3,2-dioxaphosphorinane, 2-sulfide derivatives for use as anti-wear additives in lubricant compositions |
| ITMI20071628A1 (it) * | 2007-08-06 | 2007-11-05 | Acs Dobfar Spa | Sintesi di 3-alchenilcefalosporine e nuovi intermedi utili ad esse correlati |
| CN101481383B (zh) * | 2008-12-31 | 2012-01-11 | 杭州奥默医药技术有限公司 | 头孢地尼酸式复盐化合物及制备方法 |
| CN102020664B (zh) * | 2010-11-30 | 2012-12-12 | 浙江工业大学 | 一种头孢地尼的合成方法 |
| CN103319503A (zh) * | 2013-06-09 | 2013-09-25 | 四川方向药业有限责任公司 | 一种头孢地尼的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK162718C (da) * | 1982-09-30 | 1992-05-11 | Fujisawa Pharmaceutical Co | Analogifremgangsmaade til fremstilling af 7-substitueret-3-vinyl-3-cephemforbindelser |
| IL99898A (en) * | 1990-11-09 | 1996-10-31 | Eisai Co Ltd | 7-Acyl-3-substituted carbamoyloxy cephem compounds their preparation and antibacterial compositions containing them |
| TW212181B (ja) * | 1992-02-14 | 1993-09-01 | Hoechst Ag | |
| CN1130908A (zh) * | 1994-07-22 | 1996-09-11 | 安蒂比奥蒂科斯公司 | 戊二酸单酰基7-氨基头孢烷酸衍生物及其制备方法 |
-
1996
- 1996-12-26 US US09/068,719 patent/US6093814A/en not_active Expired - Lifetime
- 1996-12-26 JP JP52423097A patent/JP3948628B2/ja not_active Expired - Lifetime
- 1996-12-26 DK DK96943357T patent/DK0874853T3/da active
- 1996-12-26 AT AT96943357T patent/ATE218572T1/de not_active IP Right Cessation
- 1996-12-26 ES ES96943357T patent/ES2175167T3/es not_active Expired - Lifetime
- 1996-12-26 WO PCT/KR1996/000250 patent/WO1997024358A1/en not_active Ceased
- 1996-12-26 PT PT96943357T patent/PT874853E/pt unknown
- 1996-12-26 DE DE69621649T patent/DE69621649T2/de not_active Expired - Lifetime
- 1996-12-26 EP EP96943357A patent/EP0874853B1/en not_active Expired - Lifetime
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001294590A (ja) * | 2000-04-13 | 2001-10-23 | Otsuka Chem Co Ltd | 3−ビニル−セフェム化合物の製造方法 |
| JP2008189688A (ja) * | 2001-06-05 | 2008-08-21 | Hanmi Pharm Co Ltd | 結晶性セフジニル酸付加塩及びこれを用いたセフジニルの製造方法 |
| JP2006500356A (ja) * | 2002-08-13 | 2006-01-05 | サンド・アクチエンゲゼルシヤフト | セフジニル中間体 |
| JP2006501305A (ja) * | 2002-10-01 | 2006-01-12 | アンティビオーティコス エッセ.ピ.ア. | セフジニル中間体塩 |
| JPWO2004085443A1 (ja) * | 2003-03-24 | 2006-06-29 | ア・チ・エツセ・ドブフアル・エツセ・ピー・アー | 7−[2−(2−アミノチアゾール−4−イル)−2−ヒドロキシイミノアセトアミド−3−ビニル−3−セフェム−4−カルボン酸(シン異性体)の新規結晶およびその製造方法 |
| JP2009249380A (ja) * | 2008-04-04 | 2009-10-29 | Daewoong Pharmaceutical Co Ltd | セフジニルの合成に有用な中間体及びこれを用いるセフジニルの製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2175167T3 (es) | 2002-11-16 |
| EP0874853A1 (en) | 1998-11-04 |
| EP0874853B1 (en) | 2002-06-05 |
| ATE218572T1 (de) | 2002-06-15 |
| DK0874853T3 (da) | 2002-09-23 |
| WO1997024358A1 (en) | 1997-07-10 |
| JP3948628B2 (ja) | 2007-07-25 |
| DE69621649T2 (de) | 2002-09-19 |
| PT874853E (pt) | 2002-09-30 |
| DE69621649D1 (de) | 2002-07-11 |
| US6093814A (en) | 2000-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3948628B2 (ja) | セフディニルの製造方法 | |
| US4866055A (en) | Cephalosporin derivatives and their crystalline derivatives | |
| EP0392796A2 (en) | Cephalosporin derivatives | |
| JP3143829B2 (ja) | 7−アシル−3−置換カルバモイルオキシセフェム化合物及びその製法 | |
| JP2600878B2 (ja) | 7―[2―(2―アミノチアゾール―4―イル)―2―ヒドロキシイミノアセトアミド]―3―セフェム化合物の製造法 | |
| AU654384B2 (en) | Preparation of a cephalosporin antibiotic using the syn-isomer of a thiazolyl intermediate | |
| JP4022070B2 (ja) | 新規チアゾール化合物およびその製造方法 | |
| JP4856795B2 (ja) | セファロスポリン抗生物質の製造における新規な塩 | |
| HU212782B (en) | Water-free acylating process for stereospecifical producing antibioticum cephepim-dihydrochloride-hydrate | |
| US4297279A (en) | Imidazoledicarboxylic acid derivative | |
| US5594130A (en) | Preparation of a cephalosporin antibiotic using the syn-isomer of a thiazolyl intermediate | |
| KR0174432B1 (ko) | 신규한 결정성 세프디니르 중간체 및 그의 제조방법 | |
| WO2003040148A1 (en) | A process for the preparation of cefixime via alkyl-or aryl-sulfonates | |
| JPH02117680A (ja) | 3―クロロセファロスポリン骨格を有する化合物 | |
| KR0174431B1 (ko) | 세프디니르의 제조방법 | |
| US5143911A (en) | Antibiotic c-3 di-hydroxyphenyl substituted cephalosporin compounds, compositions and method of use thereof | |
| KR100293728B1 (ko) | 결정성세피롬황산염의제조방법 | |
| US5831085A (en) | Process for manufacture of cephalosporin such as ceftazidime and intermediate thereof | |
| JP2898029B2 (ja) | セフェム誘導体ジメチルホルムアミド溶媒和結晶 | |
| KR101028689B1 (ko) | 신규한 결정성 3-머캅토-1-(아세트이미도일)피롤리딘유도체 및 그의 제조방법 | |
| JP3005273B2 (ja) | チアゾリルアセトアミド―3―セフェム系誘導体 | |
| JP2959821B2 (ja) | チアゾリルアセトアミドセフェム誘導体 | |
| JPH0576480B2 (ja) | ||
| EP0382220A2 (en) | Method for preparing aminothiazolylacetic acid derivatives | |
| JPH03204884A (ja) | チアゾリルアセトアミド―3―セフェム系誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070131 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070320 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070413 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100427 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110427 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110427 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110427 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110427 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120427 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120427 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130427 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130427 Year of fee payment: 6 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140427 Year of fee payment: 7 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |